Cost utility of telaprevir-PR versus boceprevir-PR and versus PR alone in chronic hepatitis C in the Netherlands

A Vellopoulou, M (Michel) van Agthoven, AG van der Kolk, Rob de Knegt, G Berdeaux, S Cure, F Bianic, M Lamotte

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)647-659
Number of pages13
JournalApplied Health Economics and Health Policy
Volume12
Publication statusPublished - 2014

Cite this